Following a slight dip in the last session, Eli Lilly (LLY) shares gained ~5% on Monday as Leerink Partners upgraded the ...

Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of uniQure N.V. (NasdaqGS:QURE) with a ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co., Truist Securities and LifeSci Capital are acting as ...

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...

Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.

Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering ...

Centessa Pharmaceuticals, which trades on the Nasdaq under the ticker CNTA, develops medicines that aim to transform the lives of patients with unmet medical needs. The stock’s decline reflects ...

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

Wall Street ended sharply higher on Monday, led by big gains in Nvidia, Palantir and other heavyweight AI-related companies ...